Abstract
The liver’s primary physiologic functions include: lipid, carbohydrate, and protein metabolism; coagulation factor production; albumin production; detoxification of xenobiotics; storage of vitamins and glycogen; and bile processing and secretion. Disease processes affecting these functions are usually directed at hepatocytes, blood vessels, or bile ducts within the liver, and can produce a wide spectrum of liver disease. There are three basic morphologic appearances of the failed liver: massive hepatic necrosis, chronic liver disease resulting in cirrhosis, and hepatic dysfunction without overt necrosis. Of these, cirrhosis is the most common cause of liver related deaths and is the twelfth leading cause of death in the United States. The primary pathophysiologic influence behind the vast majority of decompensating events—such as gastrointestinal bleeding—in cirrhotic patients is portal hypertension, i.e. the increased resistance to portal blood flow that creates an increased gradient of pressure between the portal vein and the inferior vena cava. When the portal pressure increases beyond 12 mm Hg, patients are prone to develop ascites, varices, and hepatic encephalopathy. Transjugular intrahepatic portosystemic shunts (TIPS) alleviate portal hypertension, and therefore some of its complications, by lowering the portal pressure below the threshold of 12 mm Hg. Still, despite advances in medical care, many patients with cirrhosis require an evaluation for liver transplantation. The Child-Turcotte-Pugh score has been a mainstay for assessing severity of cirrhosis. Additionally, the Model for End-Stage Liver Disease (MELD) score—a value ranging from 6 to 40, derived from a patient’s serum creatinine, total bilirubin, and international normalized ratio (INR)—is used to predict mortality in patients with end stage liver disease and has been used for liver transplant allocation system in the United States. Since 2016, serum sodium was formally added to the MELD equation, based on data that hyponatremia is predictive of mortality in cirrhotic patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- TIPS:
-
Transjugular Intrahepatic Portosystemic Shunt
- MELD:
-
Model for End-Stage Liver Disease
- INR:
-
International Normalized Ratio
- TACE:
-
Transarterial chemoembolization
- AST:
-
Aspartate aminotransferase
- ALT:
-
Alanine aminotransferase
- CTP:
-
Child-Turcotte-Pugh
- OPTN:
-
Organ Procurement Transplantation Network
- UNOS:
-
United Network for Organ Sharing
References
Theise ND. Liver and gallbladder. In: Kumar V, Abbas AK, Aster JC, editors. Robbins and Cotran pathologic basis of disease. Philadelphia: Elsevier Saunders; 2015. p. 821–81.
Crawford JM, Burt AD. Anatomy, pathophysiology, and basic mechanisms of disease. In: Burt AD, Portmann BC, Ferrell LD, editors. MacSween’s pathology of the liver. Edinburgh: Churchill Livingstone Elsevier; 2012. p. 1–77.
U.S. Department of Health & Human Services. Organ Procurement and Transplantation Network. http://optn.transplant.hrsa.gov. Accessed 13 May 2014.
Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000;342(17):1266–71.
Dutta A, Saha C, Johnson CS, Chalasani N. Variability in the upper limit of normal for serum alanine aminotransferase levels: a statewide study. Hepatology. 2009;50(6):1957–62.
D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–31.
D’Amico G, Pasta L, Morabito A, D’Amico M, Caltagirone M, Malizia G, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014;39(10):1180–93.
Zipprich A, Garcia-Tsao G, Rogowski S, Fleig WE, Seufferlein T, Dollinger MM. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int: Official J Int Assoc Study Liver. 2012;32(9):1407–14.
Gines P, Fernandez-Esparrach G, Arroyo V. Ascites and renal functional abnormalities in cirrhosis. Pathogenesis and treatment. Baillieres Clin Gastroenterol. 1997;11(2):365–85.
Bustamante J, Rimola A, Ventura PJ, Navasa M, Cirera I, Reggiardo V, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999;30(5):890–5.
Boyer TD, Haskal ZJ. American Association for the Study of Liver D. The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Management of Portal Hypertension: update 2009. Hepatology. 2010;51(1):306.
Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124(1):91–6.
Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol. 2004;40(6):897–903.
Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864–71.
Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–70.
Biggins SW, Bambha K. MELD-based liver allocation: who is underserved? Semin Liver Dis. 2006;26(3):211–20.
Kalra A, Wedd JP, Biggins SW. Changing prioritization for transplantation: MELD-Na, hepatocellular carcinoma exceptions, and more. Curr Opin Organ Transplant. 2016;21(2):120–6.
Smith JM, Biggins SW, Haselby DG, Kim WR, Wedd J, Lamb K, et al. Kidney, pancreas and liver allocation and distribution in the United States. Am J Transpl: Official J Am Soc Transpl Am Soc Transplant Surg. 2012;12(12):3191–212.
Biggins SW. Beyond the numbers: rational and ethical application of outcome models for organ allocation in liver transplantation. Liver Transpl: Official Publ Am Assoc Study Liver Dis Int Liver Transpl Soc. 2007;13(8):1080–3.
Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology. 2005;41(1):32–9.
Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006;130(6):1652–60.
Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359(10):1018–26.
Biggins SW. Use of serum sodium for liver transplant graft allocation: a decade in the making, now is it ready for primetime? Liver Transpl: Official Publ Am Assoc Study Liver Dis Int Liver Transpl Soc. 2015;21(3):279–81.
Garwood ER, Fidelman N, Hoch SE, Kerlan RK Jr, Yao FY. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction. Liver Transpl: Official Publ Am Assoc Study Liver Dis Int Liver Transpl Soc. 2013;19(2):164–73.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Kaplan, J.B., Kalra, A., Biggins, S.W. (2017). Liver Anatomy and Function. In: Meyer, J., Schefter, T. (eds) Radiation Therapy for Liver Tumors. Springer, Cham. https://doi.org/10.1007/978-3-319-54531-8_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-54531-8_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-54530-1
Online ISBN: 978-3-319-54531-8
eBook Packages: MedicineMedicine (R0)